Neural Control of Circulation Before and After Intravenous Urapidil in Essential Hypertension

G. Grassi, G. Parati, G. Pomidossi, G. Giannattasio, R. Casadei, A. Groppelli, A. Zanchetti, G. Mancia

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Drugs interfering with sympathetic influences on the cardiovascular system have been shown to effectively lower blood pressure in hypertension. However, sympathetic cardiovascular control is involved in blood pressure homeostasis, which means that these drugs may produce potential adverse haemodynamic effects that may reduce the benefit of their antihypertensive action. This paper summarises the results of a study in which we examinedthe effects of urapidil on the arterial baroreflex and the cardiopulmonary reflex in 6 essential hypertensive patients given 25mg of the drug intravenously. The dose of the drug used caused a marked reduction in arterial blood pressure (direct measurement). However, pressor and depressor responses to carotid baroreceptor deactivation and stimulation (neck chamber device), respectively, were not modified when compared with those observed in the placebo period. This was also the case for increases and reductions in both forearm vascular resistance and plasma noradrenaline (norepinephrine) concentrations induced by deactivating and stimulating cardiopulmonary receptors, respectively. The pressor and tachycardic responses to handgrip and cold exposure were also unaffected by the drug. It is concluded that when administered at a clinically effective dose urapidil does not adversely affect major reflex mechanisms involved in neural cardiovascular regulation. This has favourable implications for the use of the drug in clinical practice.

Original languageEnglish
Pages (from-to)104-110
Number of pages7
JournalDrugs
Volume35
Issue number6
DOIs
Publication statusPublished - 1988

Fingerprint

Blood pressure
Pharmaceutical Preparations
Reflex
Norepinephrine
Blood Pressure
Cardiovascular system
Pressoreceptors
Baroreflex
Hemodynamics
Cardiovascular System
Forearm
Vascular Resistance
Antihypertensive Agents
urapidil
Essential Hypertension
Arterial Pressure
Homeostasis
Neck
Placebos
Hypertension

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Health, Toxicology and Mutagenesis
  • Toxicology

Cite this

Neural Control of Circulation Before and After Intravenous Urapidil in Essential Hypertension. / Grassi, G.; Parati, G.; Pomidossi, G.; Giannattasio, G.; Casadei, R.; Groppelli, A.; Zanchetti, A.; Mancia, G.

In: Drugs, Vol. 35, No. 6, 1988, p. 104-110.

Research output: Contribution to journalArticle

Grassi, G, Parati, G, Pomidossi, G, Giannattasio, G, Casadei, R, Groppelli, A, Zanchetti, A & Mancia, G 1988, 'Neural Control of Circulation Before and After Intravenous Urapidil in Essential Hypertension', Drugs, vol. 35, no. 6, pp. 104-110. https://doi.org/10.2165/00003495-198800356-00015
Grassi, G. ; Parati, G. ; Pomidossi, G. ; Giannattasio, G. ; Casadei, R. ; Groppelli, A. ; Zanchetti, A. ; Mancia, G. / Neural Control of Circulation Before and After Intravenous Urapidil in Essential Hypertension. In: Drugs. 1988 ; Vol. 35, No. 6. pp. 104-110.
@article{d6510185df094a9d8ea749f68c835fac,
title = "Neural Control of Circulation Before and After Intravenous Urapidil in Essential Hypertension",
abstract = "Drugs interfering with sympathetic influences on the cardiovascular system have been shown to effectively lower blood pressure in hypertension. However, sympathetic cardiovascular control is involved in blood pressure homeostasis, which means that these drugs may produce potential adverse haemodynamic effects that may reduce the benefit of their antihypertensive action. This paper summarises the results of a study in which we examinedthe effects of urapidil on the arterial baroreflex and the cardiopulmonary reflex in 6 essential hypertensive patients given 25mg of the drug intravenously. The dose of the drug used caused a marked reduction in arterial blood pressure (direct measurement). However, pressor and depressor responses to carotid baroreceptor deactivation and stimulation (neck chamber device), respectively, were not modified when compared with those observed in the placebo period. This was also the case for increases and reductions in both forearm vascular resistance and plasma noradrenaline (norepinephrine) concentrations induced by deactivating and stimulating cardiopulmonary receptors, respectively. The pressor and tachycardic responses to handgrip and cold exposure were also unaffected by the drug. It is concluded that when administered at a clinically effective dose urapidil does not adversely affect major reflex mechanisms involved in neural cardiovascular regulation. This has favourable implications for the use of the drug in clinical practice.",
author = "G. Grassi and G. Parati and G. Pomidossi and G. Giannattasio and R. Casadei and A. Groppelli and A. Zanchetti and G. Mancia",
year = "1988",
doi = "10.2165/00003495-198800356-00015",
language = "English",
volume = "35",
pages = "104--110",
journal = "Drugs",
issn = "0012-6667",
publisher = "Adis International Ltd",
number = "6",

}

TY - JOUR

T1 - Neural Control of Circulation Before and After Intravenous Urapidil in Essential Hypertension

AU - Grassi, G.

AU - Parati, G.

AU - Pomidossi, G.

AU - Giannattasio, G.

AU - Casadei, R.

AU - Groppelli, A.

AU - Zanchetti, A.

AU - Mancia, G.

PY - 1988

Y1 - 1988

N2 - Drugs interfering with sympathetic influences on the cardiovascular system have been shown to effectively lower blood pressure in hypertension. However, sympathetic cardiovascular control is involved in blood pressure homeostasis, which means that these drugs may produce potential adverse haemodynamic effects that may reduce the benefit of their antihypertensive action. This paper summarises the results of a study in which we examinedthe effects of urapidil on the arterial baroreflex and the cardiopulmonary reflex in 6 essential hypertensive patients given 25mg of the drug intravenously. The dose of the drug used caused a marked reduction in arterial blood pressure (direct measurement). However, pressor and depressor responses to carotid baroreceptor deactivation and stimulation (neck chamber device), respectively, were not modified when compared with those observed in the placebo period. This was also the case for increases and reductions in both forearm vascular resistance and plasma noradrenaline (norepinephrine) concentrations induced by deactivating and stimulating cardiopulmonary receptors, respectively. The pressor and tachycardic responses to handgrip and cold exposure were also unaffected by the drug. It is concluded that when administered at a clinically effective dose urapidil does not adversely affect major reflex mechanisms involved in neural cardiovascular regulation. This has favourable implications for the use of the drug in clinical practice.

AB - Drugs interfering with sympathetic influences on the cardiovascular system have been shown to effectively lower blood pressure in hypertension. However, sympathetic cardiovascular control is involved in blood pressure homeostasis, which means that these drugs may produce potential adverse haemodynamic effects that may reduce the benefit of their antihypertensive action. This paper summarises the results of a study in which we examinedthe effects of urapidil on the arterial baroreflex and the cardiopulmonary reflex in 6 essential hypertensive patients given 25mg of the drug intravenously. The dose of the drug used caused a marked reduction in arterial blood pressure (direct measurement). However, pressor and depressor responses to carotid baroreceptor deactivation and stimulation (neck chamber device), respectively, were not modified when compared with those observed in the placebo period. This was also the case for increases and reductions in both forearm vascular resistance and plasma noradrenaline (norepinephrine) concentrations induced by deactivating and stimulating cardiopulmonary receptors, respectively. The pressor and tachycardic responses to handgrip and cold exposure were also unaffected by the drug. It is concluded that when administered at a clinically effective dose urapidil does not adversely affect major reflex mechanisms involved in neural cardiovascular regulation. This has favourable implications for the use of the drug in clinical practice.

UR - http://www.scopus.com/inward/record.url?scp=0023779302&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023779302&partnerID=8YFLogxK

U2 - 10.2165/00003495-198800356-00015

DO - 10.2165/00003495-198800356-00015

M3 - Article

VL - 35

SP - 104

EP - 110

JO - Drugs

JF - Drugs

SN - 0012-6667

IS - 6

ER -